About Us

What is MVS Pharma ?

Effects of pandemic on global economy

MVS Pharma GmbH is an innovative biotech and pharmaceutical start-up company located in Stuttgart, Germany. Working under a holding company, alongside with a development team for supplements in India, MVS Pharma further demonstrates its undeniable global focus on European external biologists, institutes and internal sales in Europe. Moreover, it is currently building an investment company in the USA. The managing director and owner is Rainer Proksch.

MVS Pharma has been developed out of the founder's passion for sporting activities and good health. He is convinced of the need to supply good vitamins and supplements. His concern is about the quality, purity and detailed information on the market that should be mandatory for all food supplements.

It is a common fact that nutrients are essential for everyone. In the last century, nutrient levels have been greatly reduced by mass production, over-fertilization of the soil and industrialization of fast food. Individual levels have decreased due to stress, bad environmental influence, diseases, and lack of time. We at MVS Pharma believe that people can do great things and change the world, be it through technology, social causes, charity, researching, etc. We believe that people could overcome their daily struggle as ordinary citizens only if they live healthy and efficient life.

Pharmaceutical companies to invest in
Best pharmaceutical companies to work for

Our Mission

MVS Pharma

Our mission at MVSPharma is to store supplements made from high-quality raw materials and free of harmful substances such as heavy metals or toxins. We want them to be sealed in a way that the quality is not negatively impacted due to factors such as light, heat, or lack of protective substances. At this point, we would like to call attention to the oxidation process in oils such as Vitamin D or Omega 3, which is caused entirely by the bad production of capsules and blisters. Our mission is to provide better! We support you in staying in high performance, whatever it means for you, preventing sickness, and restoring health, strength and vitality.

"Nevertheless, in parallel, we are learning in a very unpleasant way that we cannot master nature, despite new technologies. This is a tough lesson for all of us right now," said Rainer Proksch, CEO & Founder of MVSPharma. Although the world is currently in a state of emergency, we strongly believe that there is a promising world beyond COVID-19.

Due to our international contacts and sense of global responsibility, we have decided to additionally work on solutions in the area of plant research in conjunction with potential virus prevention and cure. Our team members extensively study the field and have the necessary knowledge. We are sure there must be solutions because Mother Nature have millions of plants out there, and whilst most of them are known, there are also many more unknown ones that have not been tested against viruses yet.

Furthermore, we are working on the continuation of existing aerosol research since a major problem with the current COVID virus is aerosol transmission between people. Indeed, we have identified the first, most promising solution and look forward to introducing you to further tested solutions in the near future. Our plant-based products, which will allow close proximity conversations and enable closeness between people without fear within tested time limits, is still in progress.

"Certainly a world in which we no longer have to utilize animal testing, have individually adapted drugs, can test them faster and more effectively, is also a world in which MVSPharma wants to establish itself. The future will not be like it was before. It will be different but certainly still worth living. " - Rainer Proksch, Founder & CEO of MVS Pharma

We would be delighted if you follow us here. We will be mutually beneficial, especially if you want to work with us to spread the idea of our products' potential or if you wish to invest in an ambitious company to ensure availability and accessibility for all.